Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ADAG

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Adagene Inc

ADAG
Current price
1.91 USD +0.005 USD (+0.26%)
Last closed 1.95 USD
ISIN US0053291078
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 91 863 720 USD
Yield for 12 month -34.76 %
1Y
3Y
5Y
10Y
15Y
ADAG
21.11.2021 - 28.11.2021

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China. Address: Building C14, Suzhou, China, 215123

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.75 USD

P/E ratio

Dividend Yield

Financials ADAG

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+103 204 USD

Last Year

+18 111 491 USD

Current Quarter

+103 204 USD

Last Quarter

Current Year

-823 044 USD

Last Year

+18 111 491 USD

Current Quarter

-823 044 USD

Last Quarter

EBITDA -35 228 592 USD
Operating Margin TTM -17 082.39 %
Price to Earnings
Return On Assets TTM -21.92 %
PEG Ratio
Return On Equity TTM -55.21 %
Wall Street Target Price 5.75 USD
Revenue TTM 103 204 USD
Book Value 1.07 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -87.30 %
Dividend Yield
Gross Profit TTM 103 204 USD
Earnings per share -0.74 USD
Diluted Eps TTM -0.74 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ADAG

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 243.81
Price Sales TTM 890.12
Enterprise Value EBITDA 1.12
Price Book MRQ 1.82

Technical indicators ADAG

For 52 weeks

1.33 USD 3.58 USD
50 Day MA 1.70 USD
Shares Short Prior Month 76 548
200 Day MA 2.06 USD
Short Ratio 3.28
Shares Short 69 023
Short Percent 0.18 %